Renzapride

Renzapride

Systematic (IUPAC) name
4-amino-N-[(4S,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
Identifiers
CAS Number	109872-41-5 N
ATC code	none
PubChem	CID: 3086547
IUPHAR/BPS	244
ChemSpider	16736758 Y
UNII	9073C0W4E9 Y
ChEMBL	CHEMBL289753 N
Chemical data
Formula	C16H22ClN3O2
Molecular mass	323.818 g/mol
SMILES Clc1cc(c(OC)cc1N)C(=O)N[C@@H]3CC[N@]2C[C@@H]3CCC2
InChI InChI=1S/C16H22ClN3O2/c1-22-15-8-13(18)12(17)7-11(15)16(21)19-14-4-6-20-5-2-3-10(14)9-20/h7-8,10,14H,2-6,9,18H2,1H3,(H,19,21)/t10-,14+/m0/s1 Y Key:GZSKEXSLDPEFPT-IINYFYTJSA-N Y
NY (what is this?)  (verify)

Renzapride is a gastroprokinetic agent and antiemetic which acts as a full 5-HT₄ full agonist and 5-HT₃ antagonist. It also functions as a 5-HT_2B antagonist and has some affinity for the 5-HT_2A and 5-HT_2C receptors, though it is unlikely that these properties contribute to its therapeutic effects.

Renzapride was being developed by Alizyme plc of the United Kingdom.

Clinical trials

Renzapride was being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23 April 2008, Alizyme ceased all development of renzapride, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.